Therapeutic Solutions International Announces Preliminary Data for Immune Stimulation in Advanced Cancer Patients by Commercially Available Product
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators
OCEANSIDE, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today early results of a clinical trial suggesting efficacy of its product NanoStilbene in increased activity of immune system cells termed “Natural Killer” cells in advanced cancer patients, as well as enhancing production of interferon gamma, a protein associated with suppression of cancer growth.
The study assessed whether the administration of NanoStilbene, a nanoformulation of pterostilbene, is effective at reducing inflammatory markers and augmenting immune function in 12 advanced cancer patients.
It has previously been known that pterostilbene possesses direct anticancer activity in the majority of cancers including melanoma1, glioma2, ovarian cancer3, prostate cancer4, pancreatic cancer5, breast cancer6, liver cancer7, colorectal cancer8, and various liquid tumors (leukemias)9.
“Chronic inflammation, as measured by CRP, TNF-alpha and IL-6 levels in the blood, has been reported to be immune suppressive in cancer patients10 and we sought to reduce them through orally administered NanoStilbene,” said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. “On average we saw CRP reduced by 27%, Interleukin 6 (IL-6) by 26% and TNF-alpha also by 26%. This dramatic reduction showed clinically relevant levels of downregulation of inflammatory cytokines as a result of the NanoStilbene administration.”
“The suppression of interferon gamma (IFN-g) is a hallmark of cancer immune evasion. Given that this cancer immune evasion is typically associated with inflammatory mediators such as TNF-alpha, we assessed the impact of NanoStilbene administration on the production of interferon gamma. We observed an average increase by 12% among the patients treated,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International. “The augmentation of interferon gamma production was due to the reduction of pro-inflammatory cytokines CRP, TNF-a, and IL-6, and we feel strongly that patients should be on a 300mg dose of NanoStilbene daily for the duration of their treatment, added Dr. Ichim.”
“The augmentation of natural killer cell (NK) activity is one of the most sensitive indicators of anticancer immunity we see clinically. Previous studies have shown that efficacy of antibody, as well as chemotherapy-induced cancer cell death, is dependent on NK activity. Unfortunately, cancer patients have suppressed NK activity, usually as a result of oxidative stress, therefore, it was postulated that NanoStilbene may reverse cancer associated NK depression,” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. “We observed on average an increase in NK activity of 37% in these very sick patients, validating that 300mg of nanoparticle pterostilbene (1.5 milliliters) daily was sufficient to cause such dramatic results not usually seen even with FDA approved drugs.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene visit www.nanostilbene.com.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.